All In Biotech

Drug Trial Radar · NCT05363280

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Conditions

  • Small Cell Lung Cancer
  • Renal Cell Carcinoma (RCC)
  • Non-Small Cell Lung

Interventions

  • AL8326 40 mgDrug

    Taken AL3826 at 40mg QD orally

  • AL8326 60 mgDrug

    Taken AL3826 at 60mg QD orally

  • AL8326 80 mg--stoppedDrug

    Taken AL3826 at 80 mg QD orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Optimal biological dose ( OBD )Time frame: 12 months
  2. Objective Response Rates (ORR)Time frame: 12 month
  3. ORR evaluation for NSCLC and RCCTime frame: 24 month

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Withdrawn

  • Northwestern University

    Chicago, Illinois · Completed

  • Siteman Cancer Center, Washington University

    St Louis, Missouri · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón Y Cajal

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.